Texas, USA (CU)_ The Heraeus Group announced this week that it has reached an agreement to purchase Mo-Sci Corp. and ETS Technology Holdings. ETS is the creator of Mirragen, a bioactive glass fibre wound care product that is FDA-approved resorbable synthetic skin substitute, whereas Mo-Sci is a provider of glass microspheres, fibres, and powders for medical devices.
Both firms are situated in Rolla, Missouri, and will be added to Heraeus Group’s healthcare and medical technology portfolio in Hanau, Germany. The transaction is expected to conclude by the end of 2021. Delbert Day founded Mo-Sci in 1985 to manufacture and distribute speciality glass and ceramic goods. Ted Day, his son, managed the company until his death in September 2020.
Nicolas Guggenheim, Head of Business Area Medical Technologies of Heraeus, expressed optimism over the acquisition. He said, “Across every treatment area, medical technology is changing rapidly. The acquisition of Mo-Sci and ETS gives us new capabilities to help our customers deliver innovative technologies and breakthrough treatments that will improve outcomes and patient care.”
Kimberly Day, the owner of Mo-Sci and ETS, released a press statement saying, “Prior to his passing, Ted identified Heraeus as a preferred partner to take Mo-Sci and ETS to the next stage of development. I am glad to carry this vision through to completion.”
